Webers C, Stolwijk C, Schiepers O, et al. - In this randomized-controlled trial, researchers determined how infliximab affects depressive symptoms in patients with ankylosing spondylitis (AS). The AS Study for the Evaluation of Recombinant Infliximab Therapy (ASSERT) was used as the source for data from a subgroup of patients. Randomization of patients to receive either infliximab (n = 16) or placebo (n = 7) until week 24 was done; after that, all patients were provided infliximab until week 54. Using generalized estimating equations (GEE), researchers examined the correlations between treatment group and depressive symptoms, measured with the Center for Epidemiological Studies Depression scale (CES-D, range 0–60 for best-worst) at baseline and over time. Per findings, patients with AS and active disease frequently exhibit depressive symptoms. Relative to placebo, infliximab led to improvement in these depressive symptoms in AS by ameliorating disease symptoms. The data indicated no direct correlation between CRP-mediated inflammation and depressive symptoms.